a, a N Clinical Trials
A listing of a, a N clinical trials actively recruiting patients volunteers.
Found 1863 clinical trials
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma
Primary Objectives: Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B Dose Expansion Part B: To assess the …
- 0 views
- 19 Feb, 2024
- 8 locations
Home Blood Pressure Study for Recent Stroke Survivors With High Blood Pressure *On Hold Due to Global Pandemic*
The purpose of this pilot study is to assess the feasibility of implementing a home blood pressure self-management program in a population of recent stroke survivors in the Washington, D.C. area. The investigators hypothesize that hypertensive stroke survivors in the Washington, DC area who participate in the Home Blood Pressure …
- 0 views
- 19 Feb, 2024
OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD)
OTL-200 is a cryopreserved dispersion for infusion containing autologous CD34+ cell enriched population that contains haematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A (ARSA) gene.
- 0 views
- 19 Feb, 2024
Effectiveness of Oral Health Promotion in Bottle Fed Children
Half of the patient will receive oral health promotion which emphasizing more on the benefit of stopping the bottle feeding habit, a free-flow cup and oral hygiene kit which include a toothbrush, toothpaste (1000ppm fluoride). The other half of the patient will receive standard of care oral hygiene promotion and …
- 0 views
- 19 Feb, 2024
First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies
ATRC-101-A01 is a first-in-human, Phase 1b, open-label trial to characterize the safety, tolerability, pharmacokinetics (PK), and biological activity of escalating doses of ATRC-101, an engineered, fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally-occurring human antibody.
- 0 views
- 19 Feb, 2024
Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis
Subjects enrolled in the standard of care group will receive a voucher to Weight Watchers after study completion.
- 0 views
- 19 Feb, 2024
Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease
To investigate the safety and efficacy of an orally administered dose of TW-012R in patients with Alzheimer's disease bearing PSEN1 (presenilin 1) mutations (PSEN1-AD), using a placebo group as a control. In addition, long-term safety will be examined in an open-label extension trial.
- 0 views
- 19 Feb, 2024
Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis
This leads to fewer hospital visits, a decrease of healthcare costs and decrease of risk of complications of natalizumab treatment. Objective: The objective is to test feasibility and validate safety of personalized extended interval dosing of natalizumab in a large real-life cohort across the Netherlands.
- 0 views
- 19 Feb, 2024
Using PRP and Cord Blood in Treatment of Covid -19
covid - 19 is a critical viral infection that affects humans
- 0 views
- 19 Feb, 2024
Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
Camrelizumab (SHR-1210) is a humanized anti-PD1 IgG4 monoclonal antibody.
- 0 views
- 19 Feb, 2024